229 related articles for article (PubMed ID: 23650284)
1. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.
Tien JC; Liu Z; Liao L; Wang F; Xu Y; Wu YL; Zhou N; Ittmann M; Xu J
Cancer Res; 2013 Jul; 73(13):3997-4008. PubMed ID: 23650284
[TBL] [Abstract][Full Text] [Related]
2. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
4. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Carver BS; Chapinski C; Wongvipat J; Hieronymus H; Chen Y; Chandarlapaty S; Arora VK; Le C; Koutcher J; Scher H; Scardino PT; Rosen N; Sawyers CL
Cancer Cell; 2011 May; 19(5):575-86. PubMed ID: 21575859
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
De Velasco MA; Tanaka M; Yamamoto Y; Hatanaka Y; Koike H; Nishio K; Yoshikawa K; Uemura H
Carcinogenesis; 2014 Sep; 35(9):2142-53. PubMed ID: 24986896
[TBL] [Abstract][Full Text] [Related]
8. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
9. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
11. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
12. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
[TBL] [Abstract][Full Text] [Related]
14. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
15. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
16. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
17. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Repression of SIRT3 Potentiates Mitochondrial Aconitase Activation to Drive Aggressive Prostate Cancer to the Bone.
Sawant Dessai A; Dominguez MP; Chen UI; Hasper J; Prechtl C; Yu C; Katsuta E; Dai T; Zhu B; Jung SY; Putluri N; Takabe K; Zhang XH; O'Malley BW; Dasgupta S
Cancer Res; 2021 Jan; 81(1):50-63. PubMed ID: 33115805
[TBL] [Abstract][Full Text] [Related]
19. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
20. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]